Bioprocessing Facilities 2011 Conference
June 17, 2011
August 8-9, 2011
San Diego Hilton Mission Bay
San Diego, CA
Read More
Biotech Demystified, The science behind the business
June 17, 2011
June 27-29, 2011
UC San Diego, Rady School of Management
La Jolla, CA
Read More
2009 Report on California’s Biomedical Industry
June 17, 2011
California’s biomedical industry has grown organically from ideas first germinated in the state’s universities. Through technology transfer, entrepreneurial commitment and investor financing, basic science discoveries have led to breakthrough technologies to better understand, diagnose, treat and cure a broad range of medical disorders.
Read More
Reps. Eshoo, Inslee, and Barton Introduce Pathway for Biosimilars Act
June 17, 2011
The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More
Reps. Eshoo, Inslee, and Barton Introduce Pathway for Biosimilars Act
June 17, 2011
The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More
Biotech generics: Handle with Care
June 17, 2011
One somewhat overlooked element of the Obama administration’s proposed federal budget is its desire to create the first regulatory process for government approval of so-called “follow-on biologics,” or generic versions of drugs manufactured by living organisms. These medicines are often used in treatments such as cancer, anemia, psoriasis and rare diseases, where little room for error exists.
Read More
California Companies Target Heart Disease, Cancer with more than 240 Medicines in Development
June 17, 2011
At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.
Read More
California Companies Target Heart Disease, Cancer with more than 240 Medicines in Development
June 17, 2011
At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.
Read More
BioOhio Annual Conference 2011
June 16, 2011
October 27, 2011
Embassy Suites Dublin
Dublin, OH
Read More
